FDA lifts pause on Valneva’s Ixchiq Chikungunya vaccine
French vaccines developer Valneva (Euronext Paris: VLA) announced that the US Food and Drug Administration (FDA) has removed its recommended pause in the use of Ixchiq in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for the vaccine.
Ixchiq remains indicated in the USA for the prevention of disease caused by the Chikungunya virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV. In the first quarter of 2025, Ixchiq sales increased to 3.0 million euros ($3.5 million), up from 0.2 million euros in the first quarter of 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze